A Phase II Study of PNT2258 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Trial Profile

A Phase II Study of PNT2258 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Suspended
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Rosomidnar (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms Wolverine
  • Sponsors Sierra Oncology
  • Most Recent Events

    • 24 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Jul 2018.
    • 24 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jul 2018.
    • 09 Jan 2017 According to a Sierra Oncology media release, this trial was originally conducted by ProNAi Therapeutics, Inc. but later on this company's name changed to Sierra Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top